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The prognosis of functional limb weakness:
a 14-year case-control study
Jeannette M. Gelauff,1,2 Alan Carson,1 Lea Ludwig,1 Marina A. J. Tijssen2 and Jon Stone1
See Edwards (doi:10.1093/brain/awz194) for a scientific commentary on this article.
Reliable data on the prognosis of functional motor disorder are scarce, as existing studies of the prognosis of functional motor
disorder are nearly all retrospective, small and uncontrolled. In this study we used a prospectively recruited, controlled cohort
design to assess misdiagnosis, mortality and symptomatic and health outcome in patients with functional limb weakness compared
to neurological disease and healthy control subjects. We also carried out an exploratory analysis for baseline factors predicting
outcome. One hundred and seven patients with functional limb weakness, 46 neurological and 38 healthy control subjects from
our previously studied prospective cohort were traced for follow-up after an average of 14 years. Misdiagnosis was determined in a
consensus meeting using information from records, patients and their GPs. Numbers and causes of death were collected via death
certificates. Outcome of limb weakness, physical and psychiatric symptoms, disability/quality of life and illness perception were
recorded with self-rated questionnaires. Outcome measures were compared within and between groups. Seventy-six patients (71%)
with functional limb weakness, 31 (67%) neurological and 23 (61%) healthy controls were included in follow-up. Misdiagnosis
was found in one patient in the functional limb weakness group (1%) and in one neurological control (2%). Eleven patients with
functional limb weakness, eight neurological control subjects and one healthy control subject had died. Weakness had completely
remitted in 20% of patients in the functional limb weakness group and in 18% of the neurological controls (P = 0.785) and
improved in a larger proportion of functional limb weakness patients (P = 0.011). Outcomes were comparable between patient
groups, and worse than the healthy control group. No baseline factors were independent predictors of outcome, although soma-
tization disorder, general health, pain and total symptoms at baseline were univariably correlated to outcome. This study is the
largest and longest follow-up study of functional limb weakness. Misdiagnosis in functional limb weakness is rare after long-term
follow-up. The disorder is associated with a higher mortality rate than expected, and symptoms are persistent and disabling. It
appears difficult to predict outcome based on common baseline variables. These data should help inform clinicians to provide a
more realistic outlook of the outcome and emphasize the importance of active and targeted therapy.
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Introduction
The prognosis of functional motor symptoms is unclear. Whilst
there is growing recognition that the diagnosis is normally
stable, there is a notable absence of data to guide clinicians
in answering the key question patients ask: ‘will it get better?’
There is now scientific consensus, supported by system-
atic review, that poorly conducted but widely cited early
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reports of high rates of misdiagnosis were erroneous.
Rates of diagnostic revision have been 4% since 1970
(Stone et al., 2005). But despite this, fears of misdiagnosis
are still widely expressed, and some senior clinicians still
extol the view that the diagnosis of functional symptoms
should not be made for fear of clinical error. Our own
large epidemiological study of patients presenting to neur-
ologists with symptoms lacking a pathophysiological ex-
planation, a wider phenotype than functional motor
symptoms (Carson et al., 2011), found a much lower fre-
quency of that diagnostic revision and highlighted that
actual diagnostic error was rare (4 out of 1040) (Stone
et al., 2009). However, follow-up was only 18 months
and it could be argued that many alternate diagnoses
may only become apparent after the passage of time.
The Scottish Neurological Symptoms Study also had an
intriguing secondary finding that a subgroup of patients
with dissociative seizures had an unexpectedly high
mortality rate of 5% (4 out of 80). This was partially
replicated by Duncan et al. (2012) who found the prema-
ture (575 years of age) death rate in dissociative seizures
was somewhat higher compared to the local national
death rate (0.58% compared to 0.41% per year). In
functional motor symptoms the limited available data
do not provide a meaningful answer (Crimlisk et al.,
1998; Deuschl et al., 1998; Feinstein et al., 2001; Stone
et al., 2003).
Significantly, more attention has been paid to diagnostic
accuracy than patients’ actual outcomes. We conducted a
systematic review of the prognosis of functional motor
symptoms consisting of 24 studies with a duration of
follow-up between 1.5 and 12.5 years, with only two
longer than 10 years. We found that 39% were the
same or worse at follow-up. However, most studies were
small, retrospective, performed in tertiary centres, and
without a control group. Studies were too heterogeneous
for clear predictors to emerge but a long duration between
the diagnosis and symptom onset were consistently asso-
ciated with bad outcome (Gelauff et al., 2014).
In this study we describe the long term follow-up of a
prospectively ascertained case-control cohort study of 107
patients with functional limb weakness (Stone et al., 2010,
2012b). We aimed: (i) to determine the rate and type of
misdiagnosis in the functional limb weakness group and
the neurological control group; (ii) to describe the fre-
quency and cause of death in patients with functional
limb weakness and compare it to neurological disease
and healthy control groups from the same baseline
study; (iii) to determine the outcome of limb weakness
in terms of change in the presenting symptom, physical
and psychiatric symptoms, disability/quality of life and
illness perceptions in patients with functional limb weak-
ness compared to neurological controls; and (iv) to con-
duct an exploratory analysis of baseline factors that
predict poor outcome at follow-up in the functional limb
weakness group.
Materials and methods
This study received ethical approval from the South Central –
Oxford C research ethics committee, a body representing the
UK Health Departments’ Research Ethics Service (Rec refer-
ence: 14/SC/0209). Consent was obtained according to the
Declaration of Helsinki.
Baseline
Between 2000 and 2003, 107 patients with functional limb
weakness, 46 patients with neurological disorders causing
limb weakness (the neurological controls) and 38 healthy sub-
jects (the healthy controls), were included. Patients with func-
tional and neurological limb weakness were recruited
consecutively by referral from all consultant neurologists
working in South East Scotland (population 1 million).
Inclusion criteria for patients were: weakness/paralysis of one
or more limb(s) diagnosed by a consultant neurologist as com-
pletely unexplained by organic disease for the functional weak-
ness group, and completely explained by neurological disease
in the neurological control group. Symptom onset had to be
within the previous 2 years. Patients had to be over 16, able to
consent and should not have an intellectual disability. Healthy
control subjects, without neurological disease or limb weak-
ness, were asked to take part when they visited their GP for a
cervical smear, an oral anticonceptive health check or a minor
upper respiratory tract infection. Four studies have been pub-
lished on the baseline data (Stone et al., 2010, 2012b; Ludwig
et al., 2015; Whitehead et al., 2015).
Follow-up
We located participants from the original study using the elec-
tronic record system of NHS Lothian (TRAK) and by contact-
ing GPs (in some cases via Practitioners Services Scotland).
Subjects who agreed to participate provided written in-
formed consent and were then asked to fill out a questionnaire,
either online or on paper.
Misdiagnosis
The possibility of misdiagnosis was assessed from three over-
lapping sources: patients were asked if ‘a new diagnosis which
explains the weakness at the time of the baseline study’ had
occurred during follow-up. The patients’ GPs were asked the
same question by means of a short postal questionnaire. Third,
the electronic records system of NHS Lothian was searched to
find any indication of misdiagnosis during the follow-up
period. Records were classed as ‘reviewed’ if at least one med-
ical record was available from 2012 onwards.
A consensus meeting (J.S., A.C. and J.G.) was held to review
these data and determine whether the initial symptoms of func-
tional or neurological limb weakness could, with the benefit of
hindsight, be explained better by another diagnosis. Not all
diagnostic revision represents a ‘misdiagnosis’ and we categor-
ized patients according to the classification of Stone et al.
(2009).
Deaths
We contacted the National Records of Scotland and England
to determine if participants had deceased during the follow-up
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period. The primary and secondary cause of death was ex-
tracted from death certificates. The UK uses WHO criteria in
which the primary cause of death is the disease or event that
started the chain of events that led to death, the secondary
cause is either a consequence or complication of the primary
cause, or another disease, which might have contributed. These
were then evaluated against the clinical data from the initial
presentation.
Outcome
Outcome in patients and controls was measured by question-
naires. Change in severity of limb weakness in both patient
groups was rated on a 6-point Likert scale ranging from ‘com-
pletely remitted’ to ‘much worse’. Rates of depression and
anxiety were measured using the Hospital Anxiety and
Depression Scale (HADS). Overall symptom burden was mea-
sured using the current physical symptoms list on the adapted
Illness Perceptions Questionnaire (IPQ). Disability/quality of
life was assessed using the Medical Outcome Study Short
form 36 items (SF36) and the Work and Social Adjustment
Scale (WSAS) and questions on whether or not the subject was
in work or studying, receiving social and/or health-related
benefits. Illness perceptions in patients were measured using
selected items from the IPQ (‘My illness is likely to be perman-
ent rather than temporary’, ‘My illness is a mystery to me’,
‘stress or worry was a cause for your weakness’, ‘damage to
the nervous system was a cause for your weakness’) scored on
a 5-point Likert scale. Patients were asked if they received any
treatment, and if so, if this was physiotherapy, psychotherapy
and/or any other treatment during the follow-up period.
Treatment was not explored further, because patients’ recall
of details of treatment was considered biased and unreliable
after 12–16 years of follow-up.
Prognostic factors
Several baseline variables were selected for a prognostic factor
analysis to predict change in severity of limb weakness [as
measured by the Clinical Global Impression (CGI) scale], and
for the post hoc comparison of patients in follow-up, not in
follow-up and deceased, in order to find potential selection
bias and predictors of death.
The selection of prognostic baseline variables (Table 4) was
based on our systematic review on the prognosis of functional
motor disorders (Gelauff et al., 2014), complemented with
variables that predicted functional versus neurological limb
weakness at baseline (Stone et al., 2010). Prognostic factors
were only assessed in the functional weakness group.
Most of these factors were based on standardized question-
naires (Stone et al., 2010). Deprivation category was deter-
mined based on postcode data (which is a measure of
socioeconomic deprivation), registration of appendectomies
and hysterectomies was part of the baseline inventory, as a
marker of vulnerability to functional disorders. Change in se-
verity of limb weakness, as measured by the CGI was used as
the outcome measure.
Statistical analysis
All patients were analysed in their initial group, irrespective
of possible misdiagnosis. Misdiagnosis was reported as a per-
centage in both patient groups. The standardized mortality
ratio (expected deaths based on national reports/measured
deaths) was calculated for both patient groups. The number
of people that died in Scotland from 2000 to 2015 was ex-
tracted from the National Records of Scotland. As patients
were included in our study from 2000 to 2003, standardized
mortality ratios for the cohorts from 2000, 2001 and 2002
up and until 2015 were compared to the corresponding co-
horts in Scotland separately and a weighted mean standar-
dized mortality ratio was calculated. Baseline characteristics
of subjects in follow-up, not in follow-up and the deceased
were compared between the three groups using non-paramet-
ric testing, in order to find potential selection bias and
predictors of death (Chi square, Kruskall-Wallis and Mann-
Whitney U-test). Baseline factors that were found to have a
prognostic value, were selected post hoc for this comparison.
No prognostic analyses were performed in patients who had
deceased.
Patient outcomes were compared between (follow-up) and
within group (follow-up versus baseline). Group comparisons
with normally distributed continuous data were tested with
t-tests (normal or paired for repeated measures). Continuous
and categorical data that were not normally distributed were
tested using non-parametric methods: Mann-Whitney U- or
Chi square tests (between-group analysis), Wilcoxon Signed
Rank tests (within-group analysis).
Prognostic factors were determined in the functional weak-
ness group using binary logistic regression analysis. Weakness
severity, the dependent variable, was dichotomized into same/
worse (bad) or better/remitted (good). Univariate testing was
carried out for all baseline factors, all factors that reached a P-
value5 0.05 were subsequently included in a multivariate ana-
lysis. The multivariate binary logistic regression was carried
out using backwards elimination.
Additionally, correlations using the non-parametric
Spearman’s rho, were made between outcomes and the
change from baseline to outcome, to determine if bad out-
come of limb weakness is correlated to bad outcome in other
domains. Also, correlations were made between improvement
of secondary outcome measures and weakness outcome, to
determine factors that might be interesting for targeting
treatment.
All missing data were reported, no imputation methods were
used. To correct for multiple comparisons, we handled inter-
pretation of P-values cautiously and considered P-
values4 0.01 to be insignificant.
Data availability
Data supporting findings can be made available on reasonable
request to lead author and subject to appropriate data hand-
ling rules. Our original consent procedures from 2000 to 2003
do not allow for individual patient data to be released.
Results
The mean follow-up duration was 14 years for patients
with functional limb weakness and neurological control
subjects (range 12–16 and 13–15 years, respectively) and
13 years for healthy control subjects (range 12–15 years).
Figure 1 shows a flow chart of follow-up, including
Prognosis of functional limb weakness BRAIN 2019: 142; 2137–2148 | 2139
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misdiagnosis, deaths and patient outcome. Neurological
controls that took part in the follow-up study had the
following baseline diagnoses: multiple sclerosis (n = 12),
Guillain-Barre´ (n = 4), transverse myelitis (n = 3), clinically
isolated syndrome (n = 1), ganglionopathy (n = 1), ulnar
neuropathy (n = 1), and myasthenia gravis (n = 1). From
those who were lost to follow-up, 14 of 19 patients with
functional limb weakness, 10 of 11 neurological control
subjects and six of seven healthy patients had either def-
initely or probably moved out of South East Scotland.
When patients in follow-up and not in follow-up were
compared at baseline (Supplementary Table 1), patients
in the functional weakness group who were not in
follow-up had a higher percentage of somatization dis-
order (42% versus 20%, P = 0.02). In the neurological
control group, patients in follow-up had a significantly
worse general health, compared to the group not in
follow-up. The healthy control group did not show any
differences.
Misdiagnosis
Sufficient data were available to determine whether there
had been a change in diagnosis in 85% of the baseline
cohort, comprising 89 patients with functional limb weak-
ness and 41 neurological control subjects. The data came
from electronic records alone (n = 49), and a combination
of the patient and/or the GP and/or electronic records
(n = 40) (Table 1).
In the functional limb weakness group, one patient had a
diagnosis of multiple sclerosis, which, with hindsight could
have been diagnosed at baseline with the information avail-
able at that time. However, it should be noted that this
patient still had functional neurological symptoms comor-
bid to multiple sclerosis symptoms at follow-up. In add-
ition, six patients developed a neurological disorder
during the follow-up period that could not explain the ini-
tial functional limb weakness. In three of those patients
(Huntington’s disease, Parkinson’s disease and idiopathic
cerebellar degeneration), the consensus view was that
whilst the disorder would not have directly explained the
symptom of functional limb weakness, the prodromal
phase of the neurological condition may have contributed
to the development of functional weakness. Prodromal
phases of neurodegenerative diseases may promote func-
tional disorders for many reasons, including altered som-
atosensory perception of the limb, or because of alterations
in cognition and emotions, especially in relation to atten-
tional processing. In the three cases of ischaemic stroke
there were strong reasons to argue the initial functional
limb weakness was not related (onset, anatomical location
or normal MRI at baseline) and was therefore not con-
sidered a transient ischaemic attack or stroke. Finally, for
one patient there was uncertainty, at follow-up, whether
this patient had a combination of a functional disorder
and multiple sclerosis with very limited symptomatology,
or only a functional disorder.
In the neurological control group, one patient was cate-
gorized as misdiagnosis. The diagnosis of common peroneal
palsy was, with the benefit of hindsight, an early sign of
spinal muscle atrophy (the stated cause of death in this
patient) and therefore labelled as misdiagnosis. One patient
developed functional symptoms during follow-up on top of
the neurological diagnosis and is therefore categorized as
‘de novo development of ‘functional disorder’. Two neuro-
logical control subjects with a single episode of demyelin-
ation at baseline, developed more episodes, therefore the
diagnosis changed to multiple sclerosis. Table 1 summarizes
these findings.
Deaths
In 101 patients with functional limb weakness (94%), 45
neurological control subjects (94%) and 30 healthy control
subjects (79%) we had sufficient information to determine
if they had died during follow-up. Eleven patients with
functional limb weakness, eight neurological control sub-
jects and one healthy control subject had died.
The causes of death are shown in Table 2. Within the
functional group, the deceased were older at symptom
onset, had a worse general health and were in a lower
deprivation category at baseline, compared to all other pa-
tients with functional limb weakness. No such differences
were found within the neurological control group. There
was no difference in the number of smokers or opioid
users between the deceased group and the other patients
at baseline (Supplementary Table 1), although the absolute
values of the numbers of smokers were 25% in follow-up
compared to 45% in the deceased group, raising the pos-
sibility of a type 2 error due to small numbers.
The primary cause of death in the functional limb weak-
ness group were all non-neurological. In three cases the
secondary cause of death was a neurological disorder that
patients developed after their initial episode of functional
weakness; these cases (two with an ischaemic stroke unre-
lated to initial presentation and one suffering from idio-
pathic cerebellar degeneration) were discussed above. For
two patients no death certificates were available in the UK
and we were unable to trace location of death outside of
the UK.
In the neurological control group, six out of eight pa-
tients’ deaths were related to their initial known diagnoses,
either as a primary or secondary cause of death [glioblast-
oma (n = 2), multiple sclerosis (n = 2), motor neuron dis-
ease/spinal muscular atrophy (n = 2)].
The (weighted mean) standardized mortality ratio for the
death rate under 75 years of age for the functional weak-
ness group was 1.48 and 2.4 for the neurological control
group.
Patient outcomes
Table 3 shows all outcome measures at baseline and
follow-up for the three groups.
2140 | BRAIN 2019: 142; 2137–2148 J. M. Gelauff et al.
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Functional limb weakness symptom outcome
Functional limb weakness completely remitted in 20%, im-
proved in 31% (14% much improved, 17% improved) and
remained the same or worsened in 49% (23% same, 14%
worse, 12% much worse) of patients. In the neurological
control group, limb weakness completely remitted in 18%,
improved in 8% (4% much improved, 4% improved) and
remained the same or worsened in 74% (17% same, 35%
worse, 22% much worse). A significantly larger percentage
of patients improved in the functional limb weakness group
(P = 0.011 on the Mann-Whitney U-test across all cate-
gories) but complete remission was equally low in both
groups (P = 0.785) (Fig. 2).
Depression and anxiety
Depression scores on the HADS were slightly better at
follow-up than baseline in the functional limb weakness
group, but this did not reach significance (52% at baseline
Figure 1 Flow chart follow-up. Misdiagnosis and patient outcome (including deaths) were studied in parallel in the baseline population.
Functional = functional limb weakness; Neuro = neurological control subjects; Healthy = healthy control subjects. In eight patients with functional
limb weakness, one neurological control subject and eight healthy control subjects we did not have sufficient information to determine if they had
died during follow-up. In two of 65 patients with functional limb weakness, only main outcome (acquired by phone) was available.
Table 1 Change in diagnosis during follow-up
Functional limb weakness patients (n = 89) Neurological controls (n = 41)
Change of diagnosis categorya n Follow-up diagnosis n Follow-up diagnosis
Misdiagnosis 1 Multiple sclerosis and functional disorder 1 Common peroneal nerve palsy changed to
spinal muscle atrophy
Diagnostic refinement - - 2 Clinically isolated syndrome evolving to mul-
tiple sclerosis
De novo development of new disease/
disorder
3 Ischaemic stroke 1 New functional disorder in multiple sclerosis
patient
Possible prodromal diagnostic change 3 Huntington’s disease, Parkinson’s disease,
Idiopathic cerebellar degeneration
- -
Disagreement between doctors 1 Disagreement between ‘multiple sclerosis and
functional disorder’ versus only functional
disorder
- -
aFrom Stone et al. (2009).
Prognosis of functional limb weakness BRAIN 2019: 142; 2137–2148 | 2141
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versus 37% at follow-up, above the cut-off of 8;
P = 0.137). In the neurological control group, percentage
of patients above the cut-off of 8, decreased from 41%
to 27% (P = 0.508), with no statistical difference. In the
healthy control subjects, numbers changed from 32% to
11% (P = 0.219). Follow-up depression scores in the func-
tional limb weakness group were not statistically different
from the neurological control group (P = 0.616) and scores
were worse than the healthy control group (P = 0.037).
Mean anxiety levels on the HADS were comparable in
the three groups at follow-up, using a cut-off score 48,
69% of functional weakness patients, 36% of neurological
controls and 42% of healthy controls suffered from anx-
iety, which was not statistically different.
Global symptom burden
Compared to baseline, we did not find a change in the
number of co-morbid symptoms, measured on the IPQ
symptom list, in patients with a functional disorder [base-
line median 9, interquartile range (IQR) 4, follow-up
median 8, IQR 5; P = 0.076] or neurological controls (base-
line median 8, IQR 3, follow-up median 7, IQR 5;
P = 0.986), nor a difference between patient groups at
follow-up (P = 0.292). In healthy control subjects, only
data at follow-up were available (median 3, IQR 4). They
scored significantly lower than the functional limb weak-
ness group (P5 0.001).
Disability/quality of life
At follow-up, 54% of the functional limb weakness pa-
tients reported fair or poor general health compared to
39% in the neurological control group (P = 0.122) and
9% in the healthy control group (P5 0.001). In none of
the groups was there a significant change compared to
baseline. Patients with functional limb weakness and neuro-
logical control subjects scored similarly on all subdomains
of the health-related quality of life and functioning SF36
scale at follow-up, except for pain, which was worse in the
functional limb weakness group (P = 0.018). The functional
limb weakness group scored significantly worse on almost
all of these domains (physical functioning, physical role
functioning, energy, pain) compared to the healthy control
group, except for the emotional role functioning domain
and the social functioning domain.
At follow-up in the functional limb weakness group,
41% were not employed for health-related reasons. In com-
parison, 39% versus 9% were out of work for health-
related reasons in the neurological and healthy control
groups, respectively. The work and social adjustment
scale showed similar outcomes in functional and neuro-
logical groups, while healthy controls were much less im-
paired. As at baseline, there was no statistical difference in
the number of patients in receipt of state-related financial
benefits at follow-up between functional and neurological
groups (43% versus 65%, P = 0.066).
Illness perception
At baseline, 89% of patients with functional limb weakness
agreed or strongly agreed that the limb weakness they
experienced was a mystery to them, while at follow-up
this was 51% (P5 0.001). At baseline, 23% of patients
agreed stress or worry was a causative factor for their
limb weakness, versus 19% at follow-up (P = 0.695) and
for damage to the nervous system the percentages were
31% at baseline and 32% at follow-up (P = 0.186), sug-
gesting remarkable stability of illness beliefs.
Table 2 Deceased subjects
Functional
limb weakness
(n = 101)
Neurological
controls
(n = 45)
Healthy
controls
(n = 30)
Functional
versus
neuro
Deaths 11 (11%) 8 (18%) 1 (3%) P = 0.54
Mean age at onset of symptoms (years) 47 (SD 15) 41 (SD 12) NA P = 0.310
Mean age at death (years) 56 (SD 14.2) 48 (SD 13.6) 59 P = 0.079
Cause of death Primary Secondary Primary Secondary Primary
Cardiovascular 5 2 - 1 - -
Malignancy (non-neurological) 1 - - - 1 -
Infectious disease 2 1 3 1 - -
Neurological disorder - 3 4 2 - -
Other 1a - 1 - - -
Unknown 2 - - - - -
Death related to initial presentation with
limb weakness
None - 6 (75%) - - -
Standardized mortality ratio (weighted
mean)
1.48 - 2.4 - - -
Based on data of 176 out of 191 baseline subjects (92%). Comparison of age: Mann Whitney U-test, comparison of number of deaths: Chi square test. Causes of death (both primary
and secondary) are given as stated on the death certificate. Secondary neurological disorders in the functional group were idiopathic cerebellar degeneration and ischaemic stroke
(n = 2).
aCause of death: systemic sclerosis.
SD = standard deviation.
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Treatment
Fifty-two per cent of patients with functional limb weak-
ness versus 70% of neurological control subjects
(P = 0.154) reported receiving some form of treatment for
their limb weakness during the follow-up period. Of the
patients with functional weakness, 76% reported receiving
physiotherapy at some stage during the follow-up period,
and 36% reported receiving psychotherapy. In the neuro-
logical control group, 75% reported physiotherapy, and
only one patient reported psychotherapy. Other therapies
in the neurological control group included medication for
the underlying condition.
Prognostic factors and correlations
Univariate analysis of prognostic factors in the functional
limb weakness group is shown in Table 4. Patients with
baseline presence of somatization disorder [0.22 (0.05–
0.89) P = 0.034], pain [1.04 (1.01–1.06) P = 0.007] and a
high number of physical symptoms [0.84 (0.72–0.19 = 0)
P = 0.037] were less likely to improve. Patients with a
better general health score on the SF36 at baseline [1.03
(1.00–1.05) P = 0.017] were more likely to improve. The
multivariate analysis showed none of the factors alone sig-
nificantly predicted weakness outcome. This multivariate
model provided a Cox and Snell R2 of 0.17, suggesting
that these factors were only explaining a small amount of
the variance.
In the functional weakness group, several follow-up out-
come measures: general health, physical functioning, pain,
energy, work and social adjustment and the total number
of symptoms on the IPQ symptom list, showed significant
correlations with weakness severity at follow-up
(Supplementary Table 2). Depression and anxiety did not
correlate with weakness outcome. In the neurological group
this was only the case for physical functioning. Change in
energy correlated only weakly to a change in weakness se-
verity in the functional group (rho 0.361 P = 0.004). In
the neurological group, a change in physical functioning
correlated strongly to change in weakness severity (rho
0.712, P5 0.001), and change in pain correlated moder-
ately to a change in weakness severity (rho 0.610,
P = 0.003). Any treatment during the follow-up period
did not influence weakness severity outcome in both groups.
Discussion
This study is the largest and longest prospectively recruited
follow-up study of functional limb weakness, and also in-
cludes a neurological and healthy control group. It is also
the longest follow-up study ever for any functional neuro-
logical disorder (Gelauff and Stone, 2016).
Misdiagnosis
In this study, we found only one example of clear-cut mis-
diagnosis of functional limb weakness (1/89 = 1%), which
was half the misdiagnosis rate of the neurological control
group (1/41 = 2%). In three additional patients the devel-
opment of functional limb weakness may have been part of
a non-specific prodrome to the development of a neurode-
generative condition not associated with limb weakness.
This is in line with observations that functional neuro-
logical disorders often occur in the context of recognized
neurological disease (Stone et al., 2012a; Paree´s et al.,
2013; Wissel et al., 2018).
Even accounting for these possible prodromal cases, the
misdiagnosis rate was low, and in keeping with other
recent studies of functional neurological disorders, as dis-
cussed in the introduction. Our prospectively ascertained
follow-up data were acquired over a much longer time
period than any other study and provide important evi-
dence of the stability and persistence of the symptoms in
patients with functional limb weakness. These findings
should encourage physicians to consider misdiagnosis in
this patient population no more of an issue than in other
neurological conditions. Reluctance to make a positive
diagnosis of a functional motor disorder, or diagnostic un-
certainty can powerfully impair treatment. We recommend
Figure 2 The severity of limb weakness at follow-up in the functional limb weakness group and the neurological control group.
A Mann-Whitney U-test comparing the whole scale in both groups, provided a P-value of 0.011.
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that physicians should continue to reconsider any neuro-
logical diagnosis and remain vigilant of co-morbid neuro-
logical disease, which is a powerful risk factor for all
functional disorders. Our findings create an argument for
neurologists to stay involved with the long-term manage-
ment of at least some patients with functional limb weak-
ness, to guide treatment and detect neurological disease,
sometimes occurring years after the functional symptoms
start.
Deaths
In our cohort, we found a standardized mortality ratio for
the death rate under 75 years of age for the functional
weakness group of 1.48 and of 2.4 for the neurological
control group. Duncan et al. (2014) found a death rate
of 0.58% per year in a group of patients with psychogenic
non-epileptic attacks (n = 260). This was somewhat lower
than our findings (our data converted to death rates:
0.77% per year in functional limb weakness and 1.27%
in neurological controls). In that study, as in ours, none
of the causes of death were directly related to the initial
symptoms. Cardiovascular cause of death was most fre-
quent. There are very limited data on death rates from
other follow-up studies in functional motor symptoms.
From two studies in functional weakness, one patient out
of 56 died after 12 years follow-up (Stone et al., 2003), and
5 of 64 after 5–7 years of follow-up (Crimlisk et al., 1998).
In the latter, one patient died of pneumonia due to immo-
bilization (in a tetraplegic patient), one died of possible
overdose, the others in these two studies died of cardiovas-
cular disease or malignancy. These findings correspond gen-
erally to our findings. In two retrospective studies in
movement disorders, 1 of 25 (Deuschl et al., 1998) and 3
of 88 (Feinstein et al., 2001) died, one from suicide and the
others of unrelated causes. The increased death rate in our
cohort compared to the general population may have sev-
eral causes: (i) three patients died of neurodegenerative
Table 4 Prognostic factors
Limb weakness severity (CPS)
Univariate analysis Multivariate analysis
Baseline variables Odds ratio (CI 95%) P-value Odds ratio (CI 95%) P-value
Age at onset 1.01 (0.96–1.05) 0.829 – –
Gender 1.25 (0.30–5.15) 0.757 – –
Symptom duration 0.98 (0.92–1.04) 0.474 – –
Being in work 1.13 (0.81–1.57) 0.486 – –
Benefits 0.43 (0.16–1.18) 0.100 – –
Deprivation category 0.64 (0.41–1.00) 0.050
Appendectomy 0.70 (0.24–2.10) 0.528 – –
Hysterectomy 0.30 (0.08–1.10) 0.069 – –
Psychiatric co-morbidity and childhood trauma
Depression (HADS) 0.99 (0.90–1.08) 0.769 – –
Anxiety (HADS) 0.95 (0.86–1.04) 0.273 – –
Somatization disorder (SCID) 0.22 (0.05–0.89) 0.034 0.44 (0.09–2.14) 0.312
Total psychiatric diagnoses on SCID 0.81 (0.58–1.13) 0.210 – –
Physical abuse (CTQ) 1.00 (0.89–1.13) 1.000 – –
Sexual abuse (CTQ) 1.02 (0.93–1.12) 0.723 – –
Health-related quality of life and functioning (SF36)
General health 1.03 (1.00–1.05) 0.017 1.02 (1.00–1.04) 0.085
Physical functioning 1.02 (1.00–1.03) 0.065 – –
Pain 1.04 (1.01–1.06) 0.007 1.03 (1.00–1.06) 0.030
Energy 1.01 (0.99–1.04) 0.268 – –
Illness perception (IPQ)
‘my weakness is a mystery to me’ 1.08 (0.57–2.05) 0.808 – –
‘my weakness is permanent rather than temporary’ 0.82 (0.55–1.22) 0.330 – –
‘what I do can determine if my illness gets better or worse’ 1.23 (0.77–1.96) 0.392 – –
‘damage to nervous system caused my symptoms’ 1.12 (0.70–1.80) 0.628 – –
‘stress or worry caused my symptoms’ 1.14 (0.78–1.67) 0.487 – –
‘I wish the doctor had listened more’ 0.83 (0.54–1.24) 0.353 – –
‘I have lost faith generally in doctors’ 0.96 (0.67–1.36) 0.804 – –
IPQ number of symptoms 0.84 (0.72–0.99) 0.037 0.93 (0.78–1.10) 0.375
Univariate and multivariate binary logistic regression analysis of baseline factors on two dichotomized outcome measures. For both outcome measures, the relationship of baseline
factors with good outcome is displayed. R2 (Cox and Snell) 0.17.
CPS = Change in Presenting Symptoms Scale; CTQ = Childhood Trauma Questionnaire; HADS = Hospital Anxiety and Depression Questionnaire; IPQ = Illness Perceptions
Questionnaire; SCID = Structured Clinical Interview for DSM.
Prognosis of functional limb weakness BRAIN 2019: 142; 2137–2148 | 2145
D
ow
nloaded from
 https://academ
ic.oup.com
/brain/article-abstract/142/7/2137/5510175 by guest on 27 February 2020
diseases, and their functional limb weakness may have been
part of a prodromal state; (ii) secondary effects of having
chronic illness including depression, anxiety or stress where
present; (iii) among patients with functional weakness pa-
tients, those that died had a poorer general health status at
baseline compared to the patients that survived; and (iv) it
is possible that patients with functional weakness had a
more sedentary lifestyle, because the cause of death was
often cardiovascular and a lower deprivation category
was associated with death. However other cardiovascular
factors were not found to be increased in the deceased
group, although numbers were small, so caution is due
for type 2 error.
Patient outcomes
In 80% of the functional limb weakness group, patients
still had symptoms of weakness in one or more limb(s)
after an average of 14 years follow-up, compared to 83%
of patients in the neurological control group. There was a
similar remission rate but overall better prognosis in the
functional group compared to the neurological controls.
The results are in line with our earlier retrospective
follow-up study in which 83% of 42 patients still had
weakness after 12.5 years (Stone et al., 2003). Other smal-
ler studies of outcome of patients with functional weakness,
with 10–30 patients over 0.5–6 years, found a large range
of outcomes with 10–56% being the same or worse weak-
ness at follow-up (Carter, 1949; Brown and Pisetsky, 1954;
Knutsson and Ma˚rtensson, 1985; Binzer and Kullgren,
1998).
From a scientific perspective, it would be useful to inves-
tigate the natural history of untreated patients with func-
tional limb weakness. Inevitably a large percentage of
patients received some form of treatment (52% in the func-
tional weakness group, 70% of neurological controls)
during follow-up. Treatment did not correlate to outcome.
However, the nature of these treatments remained unclear,
as our study was not focused on treatment, and the
reported treatments were not standardized or randomized.
Also, we could not reliably collect data on types of treat-
ment using self-report over a period of 14 years. One of the
authors (J.S.) saw all the patients for research assessments
at baseline between 2000 and 2003, not for specific treat-
ment. Patients were told they were in a study of ‘unex-
plained motor symptoms’ only and did not receive the
detailed explanations, supported by written materials, that
they would in Edinburgh in 2019. The impression from
review was that it was often not delivered by practitioners
experienced in functional disorders.
Mirroring the persistent nature of the symptom of func-
tional limb weakness, patients also failed to improve on
most secondary health outcome measures. Total symptom
burden and measures of disability/quality of life were all
correlated moderately to weakness severity, which (with the
exception of physical functioning) were not found in the
neurological control group. This could be due to quality of
life being more greatly determined by functional symptoms
in the functional weakness group compared to neurological
controls.
More patients with functional limb weakness were out of
work at follow-up than had been at baseline. Other studies
of patients with functional motor disorders have found a
low frequency of being in work ranging from 11% to 57%
(Binzer and Kullgren, 1998; Crimlisk et al., 1998). In our
data, patients with functional weakness were less likely to
receive benefits at follow-up (43%) than neurological con-
trols (65%), although this did not reach significance
(P = 0.066), while disability at follow-up was equal. In con-
trast to findings from the Scottish Neurological Symptoms
Study of 3781 outpatients (Carson et al., 2011), in which
patients with functional disorders in general were slightly
more likely to be on disability benefits, receipt of benefits
did not predict outcome in patients with functional limb
weakness.
Over time, financial benefits for patients with functional
limb weakness did not increase and receiving benefits did
not predict outcome, which contradicts the notion that pa-
tients would perpetuate their symptoms in order to gain
benefits.
Prognostic factors
Several factors were found to influence weakness severity at
follow-up in the univariate analysis. General health at base-
line was, perhaps unsurprisingly, found to be associated
with limb weakness outcome. Pain was also found to influ-
ence symptom outcome. From clinical practice we know
pain is an important impairing symptom for many patients
with functional limb weakness. However it has only been
studied in fixed dystonia, where it was found to be a nega-
tive predictor (Ibrahim et al., 2009). In our limb weakness
study, many patients had low pain scores at baseline
[median score 33 out of 100, (IQR 35), lower score equates
to more pain], and even worse (median 20, IQR 20,
P5 0.001) at follow-up, which was significantly worse
than the control groups. Also, a change in pain between
baseline and follow-up was correlated to general health
outcome. This highlights the importance of assessing pain
at baseline and possibly targeting it as a stratifying factor in
treatment trials.
Somatization disorder at baseline, an indicator of individ-
uals with functional symptoms in several domains, was also
found to influence limb weakness at follow-up negatively in
univariate analysis. In total, 13 patients met the criteria for
somatization disorder at baseline. Of those, 12 (92%) had
poor or fair general health and 10 (77%) had same or
worse weakness at follow-up. The two studies that have
investigated this have found no correlation between soma-
toform disorders and outcome (Crimlisk et al., 1998;
Ibrahim et al., 2009). From our data, patients with a long-
standing vulnerability to various symptoms throughout
their life, do seem to have a worse prognosis. Total
number of physical symptoms at baseline, which was also
2146 | BRAIN 2019: 142; 2137–2148 J. M. Gelauff et al.
D
ow
nloaded from
 https://academ
ic.oup.com
/brain/article-abstract/142/7/2137/5510175 by guest on 27 February 2020
found to be a univariate prognostic factor, could be seen in
the same light.
The factors we included in the prognostic analysis were
determined based on previous findings in the literature and
in our baseline study, but many factors were not found to
have a prognostic value. For age and gender, this was ex-
pected based on the literature. It was however striking that
factors found to be predictive in other studies like benefits,
working status, frequency of physical and sexual abuse and
certain illness perceptions, were not prognostic (Gelauff
et al., 2014). Notwithstanding the risk of a false negative
result, as our numbers are relatively low for a multivariate
analysis, these are important observations, as many of these
factors are often suggested to play an important role in the
prognosis of functional neurological disorders.
Factors that have most consistently correlated with posi-
tive outcome in the literature included an early diagnosis
and short duration of symptoms at baseline (Knutsson and
Ma˚rtensson, 1985; Couprie et al., 1995; Factor et al.,
1995; Mace and Trimble, 1996; Crimlisk et al., 1998;
Feinstein et al., 2001; Thomas et al., 2006; Jankovic
et al., 2006; McKeon et al., 2009; Munhoz et al., 2011;
Erro et al., 2014). Symptom duration before diagnosis was
not found to be a prognostic factor in our study. However,
the original study set a maximum 2 years of symptom dur-
ation as an inclusion criterion at baseline, which means this
study could not easily investigate that issue.
Generally, we found it difficult to predict outcome in our
cohort, let alone at a patient level. Apart from the low yield
of prognostic factors, part of the problem may be hetero-
geneity between patients. Moreover, our model only ex-
plained 17% of the variance of the functional weakness
outcome, and 38% of the general health outcome, which
means other unknown factors influence outcome substan-
tially. In practice, this means that clinicians should be wary
about judging the likely outcome in individuals with func-
tional limb weakness and keep an open mind, regardless of
apparently poor prognostic features.
Limitations
Inclusion in the original study was consecutively by all
neurologists working in a regional clinical neurosciences
centre covering the South-east Scotland region, population
about one million. Our sample is likely to be representative
of the population in this region, as there are very limited
alternative neurological services in the area (limited private
care and no inpatient private neurological beds).
Incomplete ascertainment at follow-up is clearly a potential
issue. However, our follow-up rate of 71% in the func-
tional weakness group after 14 years (including the
deceased patients) is respectable given the duration of
time, and baseline variables appeared similar between re-
sponders and non-responders There was a higher percent-
age of patients with functional weakness in the group not
in follow-up with somatization disorder (42%) compared
to the group in follow-up (20%). As we found somatization
disorder to be a (univariable) predictor of bad outcome, the
higher dropout of these patients could have caused bias
towards a more favourable outcome. Patients who could
not be contacted had most commonly moved out of the
area, so are arguably less likely to be a confounding
factor. Patients declining to participate most likely intro-
duced confounding; however, whether that would be in
favour of good or bad outcome is speculative. Our results
on misdiagnosis may have been biased by the fact that
these patients were all part of a study. Patients in whom
there was doubt about the diagnosis may have been less
likely to be referred to the study. Our data on cause of
death are partly limited by accuracy of death certification.
The patient outcome data were based on self-report.
However, in previous studies comparing subjective and ob-
jective outcome measures, there has been little difference
between the two. Patients with very short duration of
symptoms were not included in this study (i.e. if they had
recovered by the time of the baseline assessment). As dur-
ation of symptoms has been found to be a negative prog-
nostic factor (Gelauff et al., 2014), prognosis may be better
in patients presenting to primary care or emergency
settings.
Conclusion
Functional limb weakness can be diagnosed accurately, and
misdiagnosis is rare even after long-term follow-up.
Functional limb weakness is persistent, disabling, and asso-
ciated with higher mortality than expected. It is very diffi-
cult to predict outcome based on common baseline
variables, although pain and propensity to longstanding
multiple functional disorders may be important stratifying
variables for clinical trials and treatment decision-making.
These data should help clinicians to provide a more realistic
prognosis for functional weakness patients and also stress
the importance of active and targeted treatment.
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